Navigation Links
CSC's FirstDoc Recognized by EMC as a Preferred Regulatory Compliance Application for Life Sciences Industry
Date:7/30/2009

FALLS CHURCH, Va., July 30 /PRNewswire/ -- CSC (NYSE: CSC) today announced an agreement with EMC Corporation to offer advanced compliance solutions to the life sciences industry. As part of the agreement, EMC will now offer CSC's FirstDoc as a preferred regulatory compliance application. FirstDoc, based on the EMC((R)) Documentum((R)) enterprise content management platform, has more than 100,000 users worldwide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090422/CSCLOGO)

"Over the last decade, FirstDoc has consistently met the highest level of certification standards set by EMC, validating the design, performance and scalability of the application," said Jay DeWalt, vice president of Indirect & Solution Sales, Content Management and Archiving Division at EMC. "The latest release of FirstDoc, based on the Documentum 6.5 platform, demonstrates CSC's continued focus on innovation and on improving the end user's experience and productivity."

"We're delighted that EMC recognizes FirstDoc as a preferred regulatory compliance application for the life sciences industry," said Nigel Whitehead, managing director of Life Sciences in CSC's Healthcare Group. "Documentum is an enterprise content management platform of choice for CSC's large and mid market customers, and we continue to design FirstDoc to take advantage of the platform's most robust features that now include access to FirstDoc and Documentum through SharePoint. We are committed to integrating FirstDoc with other complementary EMC products such as EMC Documentum Retention Policy Services, EMC Captiva InputAccel and EMC Documentum Content Transformation Services."

FirstDoc is designed to help life sciences compani
'/>"/>

SOURCE CSC
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Blue Cross and Blue Shield Initiatives Recognized for Increasing Patient Safety and Efficiency
2. Health Advocate Recognized by Inc. 500 as One of the Nations Fastest Growing Private Companies
3. J.D. Power and Associates Reports: CIGNA HealthCare Recognized for Call Center Customer Satisfaction Excellence For a Second Consecutive Year
4. J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas
5. Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction
6. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
7. J.D. Power and Associates Reports: Rush-Copley Medical Center Recognized for Third Consecutive Year for Providing an Outstanding Inpatient Experience
8. AstraZeneca Recognized as One of Working Mothers 100 Best Companies for the Sixth Consecutive Year
9. Blue Cross and Blue Shield Association Nationally Recognized by BusinessWeek and AARP for Creating a Unique Workplace Environment for New and Mature Employees
10. Higher death rates in kidney patients with newly recognized disease
11. For Second Year Beryl Recognized as a Tech Titan, One of Texas Fastest- Growing Technology Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... genetic features of pulmonary fibrosis by physicians and scientists ... lead to improved treatment of this deadly lung disease, ... . , The study found that a particular genetic ... fibrosis, a chronic progressive disease with a median survival ... researchers may want to consider including genetic testing in ...
(Date:5/21/2013)... the adenoids and tonsils, is performed 500,000 times a ... for children with obstructive sleep apnea. However, the ... functioning, behavior, sleep apnea symptoms, and quality of life ... study led by Susan Redline, MD, MPH, director ... Associate Clinic Director of the Division of Sleep Medicine ...
(Date:5/21/2013)... Today, Zane Benefits, Inc. published a new ... Zane Benefits, which provides comprehensive and flexible alternatives to ... defined contribution and http://HRA Link: ... Zane Benefits’ website, the Affordable Care Act (known as ... 2010 and impacts many areas of health care and ...
(Date:5/21/2013)... 2013 A new study appearing in ... that stem cells harvested from fat (adipose) are more ... to modulate the body’s immune system. , The ... therapies, as adipose tissue-derived stem cells (AT-SCs) are far ... bone marrow and can be collected from waste material ...
(Date:5/21/2013)... 21, 2013 Octo Consulting Group, ... management consulting solutions to the Federal marketplace, has ... In the newly created role, Denny will ... of the firm’s business development function to include ... functions, and leading strategies to achieve the firm’s ...
Breaking Medicine News(10 mins):Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2
... Department of Antiquities of Syria and the University of Chicago ... fought in upper Mesopotamia// in 3500 B.C., leading to the ... that the entire area where the excavation was conducted was ... by the archeologists. Hamoukar is in Syria at the Iraqi ...
... related to Food science and consumer acceptance in Norway ... then do experts to cheese.// ,The food compared ... with expert dairy assessors. The rating was based on ... ,There was difference of opinion in both factions. As ...
... will be spending $60 million to buy 1.8 courses ... //Australian Health Minister Tony Abbott confirmed the order yesterday. ... to pharmaceuticals giant GlaxoSmithKline, but Biota had alleged that ... this allegation. This fresh order makes it the third ...
... has been conducted on a six-year-old Pakistani boy at the ... his birthday on 19 December 2005. //,Anupam Sibal, Medical Director ... in ICU but is responding well to medication. Doctors are ... be normal soon.' , ,He refused to give further ...
... Yoga, Acupuncture, Ayurveda, Chinese movement therapies such as ... just some of the commonly used alternative treatments ... Europe. //Perhaps, this is because it’s strongly perceived ... treatment for cancer with the combination of some ...
... of James Cook University's (JCU) has urged the Health ... the University which will help to produce more doctors ... graduation day.// James Cook University is Australia's premier tropical ... The University is named after the British explorer, Captain ...
Cached Medicine News:Health News:Excavations Reveal Clues Of Early Warfare 2
(Date:5/21/2013)... 2013 Hurel Corporation ("Hurel"), a world-leading provider ... platforms, today announced the appointment of James ... Board of Directors. Dr. MacDonald is the former Executive ... Institute ("SPRI"), which was the pharmaceutical development arm of ... Co. in 2009. Over a career that ...
(Date:5/21/2013)... ALLENTOWN, Pa. , May 21, 2013  Lehigh ... additional TRU-D SmartUVC TM devices, adding to its ... With seven devices taking up residence within the network, ... in the U.S. to proactively combat superbugs and provide ... Short for Total Room Ultraviolet Disinfector, TRU-D – the ...
(Date:5/21/2013)... May 21, 2013  Janssen R&D Ireland (Janssen) ... the global Phase 3 PROMISE study demonstrating that ... led to sustained virologic response 12 weeks after ... of treatment-experienced genotype 1 chronic hepatitis C adult ... of liver fibrosis, when administered once daily with ...
Breaking Medicine Technology:Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... Disease Week data highlight effects of AMITIZA in ... ... results indicated that,treatment with AMITIZA(R) (lubiprostone) 8 mcg lead to significant ... were presented at Digestive Disease Week (DDW) 2008, the,largest annual international ...
... Five Oral Presentations at ASCO Annual Meeting Will Further ... Front-line Multiple Myeloma -, CAMBRIDGE, Mass., May 16 ... new data from VELCADE,clinical studies are scheduled to be ... Annual Meeting in Chicago, Illinois, May 30 -,June 3, ...
Cached Medicine Technology:New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 2New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 3New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 4New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 5New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 6New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8
... system was expressly designed to obtain the ... special source and an equally special power ... particular high energy impulses with constant peak ... 'top-flat shaped') allow storage of enough energy ...
... Derm is a KTP laser, very compact ... nm (frequency doubled Nd:YAG) for dermatologic treatments. ... comfortable color LCD Touch-screen. Maximum power ... 0.3, 0.5, 0.7 and 1.0 mm. SmartLite ...
... Erbium (Er:YAG) laser is the ideal instrument ... Smart 2940 Plus, the majority of surface ... a wide range of scar tissue, with ... most cases with the elimination of anaesthetics, ...
... is the result of DEKA s ... of three different methods capable of ... skin. This treatment is designed to ... through the combined action of a ...
Medicine Products: